Methods of treatment using a gastric retained gabapentin dosage
View Patent ↗A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
1. A dosage form comprising:
a core comprising gabapentin and a pharmaceutically acceptable excipient, and a semipermeable membrane surrounding the core, the semipermeable membrane comprising a plasticizer and being permeable to a fluid in an environment of use and substantially impermeable to unsolubilized gabapentin,
wherein the dosage form as formulated is of sufficient has a size to promote retention in the upper gastrointestinal tract of a subject in a fed mode for a period of about 5 hours, and wherein at least about 80 wt % of the gabapentin is released from the dosage form in about 5-12 hours via controlled release through the semipermeable membrane.
2. The dosage form of claim 1 , wherein the core comprises about 300 mg gabapentin.
3. The dosage form of claim 1 , wherein the core comprises about 600 mg gabapentin.
4. The dosage form of claim 1 , wherein the semipermeable membrane comprises a material selected from the group consisting of acetaldehyde dimethyl acetate, acetaldehyde dimethylcellulose acetate, agar acetate, alkylene oxide and alkyl glycidyl ether copolymers, amylose triacetate, beta glucan acetate, beta glucan triacetate, cellulose esters, cellulose ethers, cellulose ester-ether polymers, mono-, di- and tricellulose acrylates, mono-, di- and tricellulose alkenylates, hydroxylated ethylene-vinyl acetate, polyamides, polyalkylene oxides, polyether and polyamide copolymers, polyglycolic acid, polylactic acid, poly(methacrylate) copolymer salts, cross-linked poly(sodium styrene sulfonate), crosslinked polystyrenes, polyurethanes, polyvinyl alcohol, crosslinked poly(vinylbenzyltrimethyl ammonium chloride), polyvinyl chloride, poly(vinylmethyl ether) copolymers, polyvinylpyrrolidone, propylcarbamate, sulfonated polystyrenes, and triacetate of locust gum bean.
5. The dosage form of claim 1 , wherein the semipermeable membrane comprises a material selected from the group consisting of cellulose esters, cellulose ethers, polyalkylene oxides, polyvinyl alcohol, and polyvinylpyrrolidone.
6. The dosage form of claim 4 , wherein the cellulose ester is selected from the group consisting of mono-, di- and tricellulose acetates, cellulose acetate butyl sulfonate, cellulose acetate butyrate, cellulose acetate chloroacetate, cellulose acetate dimethylaminoacetate, cellulose acetate ethyl carbamate, cellulose acetate ethyl carbonate, cellulose acetate ethyl oxalate, cellulose acetate laurate, cellulose acetate methyl carbamate, cellulose acetate methyl sulfonate, cellulose acetate octate, cellulose acetate phthalate, cellulose acetate propionate, cellulose acetate succinate, cellulose acetate p-toluene sulfonate, cellulose acetate valerate, cellulose propionate, cellulose propionate succinate, dimethyl cellulose acetate, mono-, di- and tricellulose acrylates, mono-, di- and tricellulose alkanylates, mono, di and tricellulose aroylates, cellulose triacylates, and cellulose diacylates.
7. The dosage form of claim 4 , wherein the cellulose ether is selected from the group consisting of ethyl cellulose, hydroxyethylcellulose, hydroxypropylcellulose, and methylcellulose.
8. The dosage form of claim 1 , wherein the plasticizer is selected from the group consisting of acetylated monoglycerides, dibutyl phthalate, diethyl phthalate, isopropyl phthalate, dimethyl phthalate, dactyl phthalate, dibutyl sebacate, dimethyl sebacate, esters, fatty acids, glycols, oils, glycerin, glycerol, glycerol monostearate, and triacetin.
9. The dosage form of claim 1 , wherein the plasticizer is selected from esters and fatty acids.
10. The dosage form of claim 9 , wherein the ester is selected from the group consisting of acetyl triethyl citrate, acetyl tributyl citrate, citrate ester, dibutyl sebacate, tetraethyl acetate, and triethyl citrate.
11. The dosage form of claim 9 , wherein the fatty acid is stearic acid.
12. The dosage form of claim 1 , wherein the semipermeable membrane comprises ethyl cellulose, stearic acid, and polyvinylpyrrolidone.
13. The dosage form of claim 1 , wherein the semipermeable membrane comprises ethyl cellulose, stearic acid, and hydroxypropylcellulose.
14. The dosage form of claim 1 , wherein the semipermeable membrane comprises polyvinyl alcohol.
15. The dosage form of claim 14 , wherein the polyvinyl alcohol is a blend of a water soluble polyvinyl alcohol and a water insoluble polyvinyl alcohol.
16. The dosage form of claim 14 , wherein the polyvinyl alcohol is crosslinked.
17. The dosage form of claim 1 , wherein the dosage form allows for the extended release of the gabapentin in the stomach and small intestine of a mammal.
18. The dosage form of claim 1 , wherein at least 40 wt % of the gabapentin is retained in the dosage form after 1 hour.
19. The dosage form of claim 1 , further comprising a second therapeutic agent selected from the group consisting of a hydantoin, an iminostilbene, a valproate, a phenyltriazine, a barbiturate, a dexoybarbiturate, a benzodiazepine, a carbamate, an anticonvulsant other than gabapentin, a tricyclic antidepressant, levadopa, carbidopa, an opioid, lithium, carbamazepine, valproate, trifluoperazine, clonazepam, risperidone, lorazepam, venlafaxine, clozapine, olanzapine, a neuroleptic, a serotonin reuptake inhibitor, buproprion, nefadone, venlaxatine, nefadone, diazepam, oxazepam, a dopaminergic agent, clonazepam, a triptine and ergotamine.
20. The dosage form of claim 1 , wherein the pharmaceutically acceptable excipient is a diluent selected from the group consisting of calcium sulfate, cellulose, dicalcium phosphate, kaolin, lactose, mannitol, microcrystalline cellulose, sodium chloride, sorbitol, starch and sucrose.